ArticleAdvances in laboratory medicine2021
Biomarkers in Alzheimer's disease.
Article in Advances in laboratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Article
- Article
- P-tau217 as a Biomarker in Alzheimer's Disease: Applications in Latin American Populations.International journal of molecular sciences · 2025Review
- d‑Glucose-Conjugated Benzo[ACS medicinal chemistry letters · 2025Article
- Neurofibrillary tangles predict dementia in patients with carotid stenosis.Journal of vascular surgery · 2025Article
- Preclinical Cognitive Markers of Alzheimer Disease and Early Diagnosis Using Virtual Reality and Artificial Intelligence: Literature Review.JMIR medical informatics · 2025Review
- Thionine modulates tau phosphorylation in an Alzheimer's disease cell culture model.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Review
- Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases.Frontiers in neurology · 2024Review
- Data Mining of Microarray Datasets in Translational Neuroscience.Brain sciences · 2023Review
- Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits.International journal of molecular sciences · 2023Review
- Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning.Sensors (Basel, Switzerland) · 2023Review
- The Future of Precision Medicine in the Cure of Alzheimer's Disease.Biomedicines · 2023Review
- The need for a tailored national dementia plan in Ethiopia: A call for action.Frontiers in neurology · 2023Review
- Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders.International journal of molecular sciences · 2022Review
- Logogenic Primary Progressive Aphasia or Alzheimer Disease: Contribution of Acoustic Markers in Early Differential Diagnosis.Life (Basel, Switzerland) · 2022Article
- The Role of High-Density Lipoprotein in Lowering Risk of Dementia in the Elderly: A Review.Cureus · 2022Review
- Characterizing Network Selectiveness to the Dynamic Spreading of Neuropathological Events in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD using biomarkers that reflect the underling neuropathology is needed. Content: The aim of this review is to describe the main outcomes when measuring classical and novel biomarkers in biological fluids or neuroimaging. Summary: Nowadays, there are three classical biomarkers for the diagnosis of AD: Aβ42, t-Tau and p-Tau. The diagnostic use of cerebrospinal fluid biomarkers is limited due to invasive collection by lumbar puncture with potential side effects. Plasma/serum measurements are the gold standard in clinics, because they are minimally invasive and, in consequence, easily collected and processed. The two main proteins implicated in the pathological process, Aβ and Tau, can be visualized using neuroimaging techniques, such as positron emission tomography. Outlook: As it is currently accepted that AD starts decades before clinical symptoms could be diagnosed, the opportunity to detect biological alterations prior to clinical symptoms would allow early diagnosis or even perhaps change treatment possibilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.